Protagenic Begin Period Cash Flow from 2010 to 2024

PTIX Stock  USD 1.50  0.01  0.67%   
Protagenic Therapeutics Begin Period Cash Flow yearly trend continues to be fairly stable with very little volatility. Begin Period Cash Flow will likely drop to about 204.4 K in 2024. Begin Period Cash Flow is the amount of cash Protagenic Therapeutics has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
1995-09-30
Previous Quarter
153.3 K
Current Value
153.3 K
Quarterly Volatility
5.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Selling General Administrative of 1.1 M or Total Revenue of 0.0, as well as many exotic indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Protagenic Therapeutics Technical models . Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Latest Protagenic Therapeutics' Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of Protagenic Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Protagenic Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Very volatile
   Begin Period Cash Flow   
       Timeline  

Protagenic Begin Period Cash Flow Regression Statistics

Arithmetic Mean601,895
Geometric Mean293,054
Coefficient Of Variation125.49
Mean Deviation451,699
Median399,687
Standard Deviation755,333
Sample Variance570.5B
Range3.1M
R-Value0
Mean Square Error614.4B
R-Squared0.0000065
Significance0.99
Slope430.53
Total Sum of Squares8T

Protagenic Begin Period Cash Flow History

2024204.4 K
2023215.2 K
2022541.2 K
2021671.1 K
2020798.6 K
2019362.5 K
2018399.7 K

About Protagenic Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Protagenic Therapeutics income statement, its balance sheet, and the statement of cash flows. Protagenic Therapeutics investors use historical funamental indicators, such as Protagenic Therapeutics's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Protagenic Therapeutics investors may use each financial statement separately, they are all related. The changes in Protagenic Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Protagenic Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Protagenic Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Begin Period Cash Flow215.2 K204.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Protagenic Therapeutics is a strong investment it is important to analyze Protagenic Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Protagenic Therapeutics' future performance. For an informed investment choice regarding Protagenic Stock, refer to the following important reports:
Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Protagenic Stock analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
CEOs Directory
Screen CEOs from public companies around the world
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Transaction History
View history of all your transactions and understand their impact on performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is Protagenic Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. If investors know Protagenic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagenic Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.15)
Return On Assets
(0.46)
Return On Equity
(0.94)
The market value of Protagenic Therapeutics is measured differently than its book value, which is the value of Protagenic that is recorded on the company's balance sheet. Investors also form their own opinion of Protagenic Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagenic Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagenic Therapeutics' market value can be influenced by many factors that don't directly affect Protagenic Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagenic Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagenic Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.